New & Notable
Novo Nordisk's amycretin shows competitive phase 2 weight loss
After yesterday's setback, Novo Nordisk released mid-stage data showing oral and injectable amycretin led to 7.6% and 11.9% placebo-adjusted weight loss, respectively, in patients with type 2 diabetes.
Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies
The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight loss and heart health, might also help combat neurodegeneration.
— Biopharma Dive
Amylin could reign supreme in the next wave of obesity drugs
With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.
— PharmaVoice
Consumer confusion fuels risky online drug purchases, survey finds
Due to widespread misunderstandings, many U.S. adults are buying drugs, especially GLP-1 products, from online, unlicensed sellers, a new survey reveals.
Pfizer wins bidding war for Metsera with $10B offer
— Biopharma DiveCMMI to launch model to lower Medicaid drug spending
— Healthcare DiveNovo, Lilly cut deal with Trump to lower prices of obesity drugs
— Biopharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Lilly advances amylin obesity drug eloralintide to phase 3 trials
Eli Lilly is set to begin late-stage clinical trials of its investigational amylin obesity drug next month, after encouraging phase 2 study results.
-
Top 10 metro areas for manufacturing biologics in 2026
Raleigh ranks as the top U.S. metro for biologics manufacturing investment in 2026, amid skilled labor shortages and shifting federal policies, a new report finds.
-
Innovent, Lilly's mazdutide outdoes Novo's semaglutide in phase 3 trial
Innovent Biologics and Eli Lilly's dual GLP-1/glucagon agonist, mazdutide, beats Novo Nordisk's semaglutide in a phase 3 trial of adults with diabetes and obesity.
-
Report: Bipartisan support for patent reform to lower drug prices
Four in five Americans support changing patent laws to lower drug costs, favoring patent reform over government price controls by 15 points, says a new I-MAK report.
-
Report: Compounded GLP-1 drugs pose safety, quality risks
Compounded GLP-1 drugs pose safety and quality risks, a recent report says, adding to the growing calls for tougher regulatory enforcement.
-
CVS Rx Report: 5 latest trends influencing community pharmacy
CVS Health's 2025 Rx Report highlights key community pharmacy trends, showing how patient needs, workforce pressures and sustainable care models are shaping care.
Features
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.
-
Expanding clinical trial access through technology, support
Systemic barriers continue to restrict clinical trial access, but when deployed correctly, technology can provide patient–provider support and close interoperability gaps.
-
Will the FDA's green list end illegal GLP-1 compounding?
The FDA recently created a green list to regulate imported GLP-1 drug ingredients, yet experts say that weak enforcement could allow illegal compounding operations to continue.
-
Using AI to identify, expose online drug counterfeiters
Pharmaceutical companies are leveraging AI's advanced detection and enforcement tools to combat the online counterfeit drug market, protecting brand integrity and consumer safety.